yahoo_financeOriginal article
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
Trial StartHMPL-A830Positive
AI Analysis
Summary
HUTCHMED has initiated a global clinical trial of HMPL-A830, a KRAS-EGFR-antibody conjugate therapy, in patients with solid tumors.
Clinical Trial Data
Outcome Details
Initiation of global trial of KRAS-EGFR-antibody conjugate HMPL-A830 in patients with solid tumors
Importance:5/10
Sentiment:
0.40
oncologyantibody-drug conjugateKRASEGFRsolid tumorstrial initiation
Related Companies
Read the original article
Published by yahoo_finance on September 28, 2026 12:00 AM